| Name | Title | Contact Details |
|---|
ICON is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. We specialise in the strategic development, management and analysis of programs that support Clinical Development - from compound selection to Phase I-IV clinical studies. In a highly fragmented industry, we are one of a small group of organisations with the capability and expertise to conduct clinical trials and development projects on either a local or global basis. We have the operational flexibility to provide development services on a stand-alone basis or as part of an integrated “full service” solution. We are also an 'end-to-end' Pharmacovigilance service provider and this includes Post Marketing Surveillance activities too.
Health Insight is a Las Vegas, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Alliqua is a provider of advanced wound care solutions. Through its sales and distribution network, together with its proprietary products, Alliqua provides a suite of technological solutions to enhance the wound care practitioner`s ability to deal with the challenges of healing both chronic and acute wounds. Alliqua currently markets its line of dressings for wound care under the SilverSeal® and Hydress® brands, as well as the sorbion sachet S® and sorbion sana® wound care products, and its TheraBond 3D® advanced dressing which incorporates the TheraBond 3D® Antimicrobial Barrier Systems technology. The Company`s Mist Therapy System® uses painless, noncontact low-frequency ultrasound to stimulate cells below the wound bed to promote the healing process. Alliqua also markets the human biologic wound care product Biovance®, as part of its licensing agreement with Celgene Cellular Therapeutics. In addition, Alliqua can provide a custom manufacturing solution to partners in the medical device and cosmetics industry, utilizing its hydrogel technology. Alliqua`s electron beam production process, located at its 16,500 square foot Good Manufacturing Practice (GMP) manufacturing facility, allows Alliqua to custom manufacture a wide variety of hydrogels. Alliqua`s hydrogels can be customized for various transdermal applications to address market opportunities in the treatment of wounds as well as the delivery of numerous drugs or other agents for pharmaceutical and cosmetic industries. The Company has locations in Langhorne, PA and Eden Prairie, MN.
Mabtech Inc is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Incyte`s vision is to become a leading biopharmaceutical company by building a proprietary pipeline of novel small molecule drugs for serious unmet medical needs primarily in the area of oncology. The field of oncology is evolving rapidly and transforming how cancer is and will be treated. With a growing pipeline that includes innovative compounds in three major oncology areas -- onco-inflammation, immuno-oncology and targeted therapies -- we believe Incyte is at the center of this transformation in cancer care. Our lead JAK inhibitor, Jakafi® (ruxolitinib), is approved for use in patients with intermediate or high-risk myelofibrosis(1). We are also pursuing FDA approval in a second related myeloproliferative neoplasm, polycythemia vera. Further, we are evaluating JAK inhibitors in multiple new indications and in combinations targeting solid tumors such as pancreatic, breast, colorectal and non-small cell lung cancer. We have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. Through strategic collaborations with Novartis and Eli Lilly, we are advancing the global development of two of our JAK1 and JAK2 inhibitor programs. Our pipeline also includes a novel immunotherapy, an oral IDO1 inhibitor, which is being evaluated alone and through multiple clinical collaborations. We also have a selective targeted therapy, an oral PI3K-delta inhibitor, which is in clinical development as monotherapy and in combination with one of our JAK inhibitors. Incyte is rooted in rigorous science, and our highly productive chemists and biologists are continuing to identify new molecules that support our goal to deliver first- and/or best-in-class medicines capable of making a difference in health care, improving the lives of patients, and building sustainable value for our shareholders.